UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy

Frontiers in immunology, 2023-04, Vol.14, p.1165394-1165394

2023

Volltextzugriff (PDF)

Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan

Clinical and experimental nephrology, 2022-04, Vol.26 (4), p.316-322

2022

Volltextzugriff (PDF)

IV. Current Treatment of IgA Nephropathy

Nihon Naika Gakkai Zasshi, 2023/05/10, Vol.112(5), pp.784-790

2023

Volltextzugriff (PDF)

IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination

Internal Medicine, 2022/04/01, Vol.61(7), pp.1033-1037

2022

Volltextzugriff (PDF)

COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine

Clinical and experimental nephrology, 2021-11, Vol.25 (11), p.1240-1246

2021

Volltextzugriff (PDF)

Pathogenesis of IgA nephropathy as a tissue-specific autoimmune disease

International immunology, 2024-07

2024

Volltextzugriff (PDF)

Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy

Science advances, 2023-03, Vol.9 (12), p.eadd6734-eadd6734

2023

Volltextzugriff (PDF)

Correction to: Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan

Clinical and experimental nephrology, 2022-04, Vol.26 (4), p.323-324

2022

Volltextzugriff (PDF)

Mucosal Immune System Dysregulation in the Pathogenesis of IgA Nephropathy

Biomedicines, 2022-11, Vol.10 (12), p.3027

2022

Volltextzugriff (PDF)

Continuous extracorporeal treatments in a dialysis patient with COVID-19

CEN case reports, 2021-05, Vol.10 (2), p.172-177

2021

Volltextzugriff (PDF)

Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy

Journal of clinical medicine, 2022-06, Vol.11 (11), p.3173

2022

Volltextzugriff (PDF)

IV. Current Treatment of IgA Nephropathy

Nihon Naika Gakkai zasshi, 2023-05, Vol.112 (5), p.784-790

2023

Volltextzugriff (PDF)

Investigation of T Cells Contributing to the Production of IgA-Type Autoantibodies Against Mesangial Cells in IgA Nephropathy: SA-PO822

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.957-957

2023

Volltextzugriff (PDF)

IgA+ Plasma Cells Accumulation in Kidneys of IgA Nephropathy Model Mice and Patients: SA-PO639

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.780-780

2022

Volltextzugriff (PDF)

Clinical Application of IgA-Type Autoantibodies Against Mesangial Autoantigen, βII-Spectrin, in IgA Nephropathy: SA-PO937

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.992-992

2023

Volltextzugriff (PDF)

Elucidating the Mechanism of Gross Hematuria in IgA Nephropathy: Analysis of the Biomarkers in Patients with Gross Hematuria After COVID-19 Vaccination: TH-PO1109

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.404-404

2023

Volltextzugriff (PDF)

Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis

Clinical kidney journal, 2023-12, Vol.16 (Supplement_2), p.ii1-ii8

2023

Volltextzugriff (PDF)

Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection

International immunology, 2023-08, Vol.35 (8), p.377-386

2023

Volltextzugriff (PDF)

Nucleotide-Sensing TLR9/TLR7 System Is a Potential Therapeutic Target for IgA Nephropathy: TH-PO546

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.243-243

2023

Volltextzugriff (PDF)

Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis

Clinical kidney journal, 2023-12, Vol.16 (S2), p.1

2023

Volltextzugriff (PDF)

The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy

Kidney international, 2023-11, Vol.104 (5), p.943-955

2023

Volltextzugriff (PDF)

Current Treatment for IgA Nephropathy and Its Rationale

Nihon Naika Gakkai Zasshi, 2021/10/10, Vol.110(10), pp.2286-2292

2021

Volltextzugriff (PDF)

Acute Tubular Injury in Patients with Severe COVID-19 Infection: PO0663

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.249-249

2020

Volltextzugriff (PDF)

WCN24-1104 Finding of CD4+ T cells infiltrating the kidney of gddY mouse, IgA nephropathy animal model

Kidney international reports, 2024-04, Vol.9 (4), p.S430-S431

2024

Volltextzugriff (PDF)

Dysregulation of B-Cell Differentiation in IgA Nephropathy Model Mice: PO1809

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.564-564

2020

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(38)

Sprache

Englisch
(34)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy

Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan

IV. Current Treatment of IgA Nephropathy

IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination

COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine

Pathogenesis of IgA nephropathy as a tissue-specific autoimmune disease

Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy

Correction to: Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan

Mucosal Immune System Dysregulation in the Pathogenesis of IgA Nephropathy

Continuous extracorporeal treatments in a dialysis patient with COVID-19

Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy

IV. Current Treatment of IgA Nephropathy

Investigation of T Cells Contributing to the Production of IgA-Type Autoantibodies Against Mesangial Cells in IgA Nephropathy: SA-PO822

IgA+ Plasma Cells Accumulation in Kidneys of IgA Nephropathy Model Mice and Patients: SA-PO639

Clinical Application of IgA-Type Autoantibodies Against Mesangial Autoantigen, βII-Spectrin, in IgA Nephropathy: SA-PO937

Elucidating the Mechanism of Gross Hematuria in IgA Nephropathy: Analysis of the Biomarkers in Patients with Gross Hematuria After COVID-19 Vaccination: TH-PO1109

Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis

Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection

Nucleotide-Sensing TLR9/TLR7 System Is a Potential Therapeutic Target for IgA Nephropathy: TH-PO546

Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis

The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy

Current Treatment for IgA Nephropathy and Its Rationale

Acute Tubular Injury in Patients with Severe COVID-19 Infection: PO0663

WCN24-1104 Finding of CD4+ T cells infiltrating the kidney of gddY mouse, IgA nephropathy animal model

Dysregulation of B-Cell Differentiation in IgA Nephropathy Model Mice: PO1809

Suchergebnisse filtern